Understanding the knowledge management needs of phenotypic screening (Santiago de Compostela, Spain)
On February 16-17, 2015 Open PHACTS successfully held a workshop in Santiago de Compostela (Spain) entitled “Understanding the knowledge management needs of phenotypic screening”.
51 people from different pharmaceutical companies and academic institutions attended the workshop. The Open PHACTS phenotypic screening workshop focused on current informatics bottlenecks of cell-based phenotypic screening and target deconvolution. The aim was to review the present computational approaches to phenotypic screens and to identify where gaps exist.
The expected outcome from this workshop was to obtain a collection of use cases relevant to phenotypic screening to be used to guide the development of the Open PHACTS Discovery Platform in assembling the necessary data sets for this domain.
The outcome of this very productive workshop was a list of prioritized use cases selected by the attendees as challenging in the knowledge frontier / computational technologies / data management in phenotypic screening and target deconvolution.
We would like to thank all attendees for coming, for their intense work and for creating the perfect atmosphere which allowed us to achieve the desired outcome easily.
More photos of the workshop can be found here.
Knowledge Management in Systems Based Phenotypic Drug Discovery: Our Experience (Victor Segarra and Arsenio Nueda, Almirall)
The Lilly Perspective: Challenges We Face & Tools We Need (Mariá Jesús Blanco and Marta Piñeiro-Núñez, Eli Lilly)
Phenotypic Drug Discovery at Esteve: Focus on Pain (Javier Burgueno and Jose Miguel Vela, Esteve)
Informatics problems and solutions for phenotypic screenings, an AstraZeneca perspective (Ola Engkvist, AstraZeneca)
Analysis of Phenotypic Hitlists (Edgar Jacoby, Janssen)
Data and Analysis in the Phenotypic World (Ceara Rea, GlaxoSmithKline)
The Open PHACTS Foundation (Bryn Williams-Jones, Open PHACTS Foundation)
Making sense out of Black box biology (Petr Bartůněk, EU-OPENSCREEN)
Phenotypic Target Discovery (Iván Cornella, Merck Research Laboratories)
Data driven challenges in phenotypic drug discovery (Martin Daffertshofer, PerkinElmer)
Phenotypic Assays (David Wild, Data2Discovery Inc.)